Resolution of inflammation: A novel therapeutic paradigm for rheumatoid arthritis and its comorbidities
Abstract
Rheumatoid arthritis (RA) is a systemic immune-mediated disease in which persistent synovial inflammation contributes not only to joint destruction but also to cardiovascular, pulmonary, metabolic, and other extra-articular complications. This review focuses specifically on the translational potential of emerging receptor-directed pro-resolving therapeutics in targeting persistent inflammation, a common mechanism driving RA and its systemic comorbidities. Although contemporary disease-modifying antirheumatic drugs (DMARDs) have substantially improved disease control and structural outcomes, a complementary therapeutic question remains: can the endogenous biological program that terminates inflammation and restores tissue homeostasis be therapeutically engaged? Resolution pharmacology addresses this question by targeting endogenous pro-resolving pathways involving specialized pro-resolving mediators (SPMs), annexin A1 (AnxA1), melanocortin receptors, the formyl peptide receptor 2 (FPR2/ALX), and related signalling networks. This review examines the evidence linking defective resolution with RA and critically evaluates the therapeutic potential of resolution-directed interventions across articular disease and major RA-associated comorbidities. Rather than treating resolution pharmacology as a uniform therapeutic class, we distinguish anti-inflammatory effects from demonstrated pro-resolving activities and evaluate evidence ranging from in vitro and animal studies to observational human studies and clinical trials. This review particularly emphasizes receptor selectivity, biased agonism, and their use in combination with established DMARD therapies. We propose that the principal opportunity for resolution pharmacology is not to replace effective DMARD therapy but to complement it, promoting inflammatory termination and tissue recovery. Thus, resolution pharmacology should currently be considered a promising translational framework requiring future clinical validation rather than an established therapeutic paradigm for RA and its comorbidities.
Related
- Cellular Metabolic Heterogeneity and Therapeutic Targeting in Rheumatoid Arthritis
- Defective macrophage plasticity exacerbates progression of inflammation in patients with rheumatoid arthritis
- Regulatory T cell dysfunction and therapeutic advances in rheumatoid arthritis, psoriasis, vitiligo, and systemic lupus erythematosus
- Pro-resolving lipid mediators and therapeutic innovations in resolution of inflammation
- Joint–brain communication in rheumatoid arthritis: glial mechanisms, pain phenotypes, and translational evidence
BibTeX
@article{yazdi2026resolution,
title = {{Resolution of inflammation: A novel therapeutic paradigm for rheumatoid arthritis and its comorbidities}},
author = {Roshanak Fekri Yazdi and Sze Ian Tan and Weifeng Bu and Brian Basto Franco and Ashton Juin Kai Ng and Hong Yong Peh and Jianmin Chen},
journal = {Pharmacological Research},
year = {2026},
month = oct,
doi = {10.1016/j.phrs.2026.109655},
url = {https://hal.science/hal-05787763v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Resolution of inflammation: A novel therapeutic paradigm for rheumatoid arthritis and its comorbidities
AU - Roshanak Fekri Yazdi
AU - Sze Ian Tan
AU - Weifeng Bu
AU - Brian Basto Franco
AU - Ashton Juin Kai Ng
AU - Hong Yong Peh
AU - Jianmin Chen
PY - 2026
DA - 2026/10/08
JO - Pharmacological Research
DO - 10.1016/j.phrs.2026.109655
UR - https://hal.science/hal-05787763v1
AB - Rheumatoid arthritis (RA) is a systemic immune-mediated disease in which persistent synovial inflammation contributes not only to joint destruction but also to cardiovascular, pulmonary, metabolic, and other extra-articular complications. This review focuses specifically on the translational potential of emerging receptor-directed pro-resolving therapeutics in targeting persistent inflammation, a common mechanism driving RA and its systemic comorbidities. Although contemporary disease-modifying antirheumatic drugs (DMARDs) have substantially improved disease control and structural outcomes, a complementary therapeutic question remains: can the endogenous biological program that terminates inflammation and restores tissue homeostasis be therapeutically engaged? Resolution pharmacology addresses this question by targeting endogenous pro-resolving pathways involving specialized pro-resolving mediators (SPMs), annexin A1 (AnxA1), melanocortin receptors, the formyl peptide receptor 2 (FPR2/ALX), and related signalling networks. This review examines the evidence linking defective resolution with RA and critically evaluates the therapeutic potential of resolution-directed interventions across articular disease and major RA-associated comorbidities. Rather than treating resolution pharmacology as a uniform therapeutic class, we distinguish anti-inflammatory effects from demonstrated pro-resolving activities and evaluate evidence ranging from in vitro and animal studies to observational human studies and clinical trials. This review particularly emphasizes receptor selectivity, biased agonism, and their use in combination with established DMARD therapies. We propose that the principal opportunity for resolution pharmacology is not to replace effective DMARD therapy but to complement it, promoting inflammatory termination and tissue recovery. Thus, resolution pharmacology should currently be considered a promising translational framework requiring future clinical validation rather than an established therapeutic paradigm for RA and its comorbidities.
SN - 1043-6618
SN - 1096-1186
ER -